Semaglutide Cuts Calories for a Full Year Even as Hunger Suppression Fades
A 60-week RCT finds semaglutide 2.4 mg sustains ~240 kcal/day reduction even after appetite benefits diminish.
Summary
A rigorous 60-week randomized controlled trial followed 120 adults with overweight or obesity taking semaglutide 2.4 mg or placebo. Participants on semaglutide consistently ate roughly 240–295 fewer calories at a measured lab lunch across all time points — at 20, 40, and 60 weeks. Interestingly, the subjective feelings of reduced hunger and food preoccupation were only significantly different from placebo at the 20-week mark, not later. Yet caloric intake remained lower throughout. This suggests semaglutide's weight-loss maintenance isn't purely driven by consciously feeling less hungry — there may be deeper metabolic or behavioral mechanisms keeping energy intake down long after the initial appetite-suppressing effects plateau.
Detailed Summary
Semaglutide (Wegovy) has reshaped obesity treatment, but a key unanswered question has been whether its appetite-suppressing effects persist long enough to maintain weight loss — or whether patients adapt and regain. This trial provides the most rigorous long-term data yet on the drug's mechanisms.
Researchers at the University of Pennsylvania randomized 120 adults with overweight or obesity in a 3:2 ratio to semaglutide 2.4 mg weekly or placebo over 60 weeks. At weeks 0, 20, 40, and 60, participants completed laboratory sessions measuring ad libitum caloric intake during a buffet-style lunch, appetite ratings after a standardized breakfast, and food reward via the validated Power of Food Scale.
The headline finding: semaglutide participants consumed significantly fewer calories than placebo at every time point — roughly 295 kcal less at week 20, 250 kcal less at week 40, and 238 kcal less at week 60. This persistent caloric deficit likely explains sustained weight loss well beyond the initial treatment phase.
However, the subjective appetite benefits — reduced hunger, less food preoccupation, and greater post-meal satiety — were only statistically significant versus placebo at week 20. By weeks 40 and 60, these group differences had disappeared. Reduced responsiveness to food cues (food reward) remained significant through week 40 but not week 60.
The dissociation between subjective appetite and actual caloric intake is clinically important. It implies that semaglutide's mechanism for maintaining weight loss may involve processes beyond conscious hunger — potentially including altered gut motility, hormonal signaling, or habituated eating behavior.
Caveats include that the study was conducted at a single academic center, relied on jump-to-reference imputation for missing data, and laboratory eating assessments may not fully reflect free-living intake. Summaries are based on the abstract only.
Key Findings
- Semaglutide reduced ad libitum caloric intake by ~238–295 kcal/day versus placebo across all 60 weeks.
- Subjective hunger suppression and food preoccupation were only significantly lower than placebo at week 20.
- Reduced food reward (responsiveness to food cues) persisted through week 40 but not week 60.
- Caloric restriction continued even after subjective appetite benefits faded, suggesting non-conscious mechanisms.
- Findings support reduced energy intake as the central driver of both weight loss induction and maintenance.
Methodology
This was a 60-week double-blind RCT enrolling 120 adults with overweight/obesity randomized 3:2 to semaglutide 2.4 mg or placebo. Laboratory assessments at weeks 0, 20, 40, and 60 measured ad libitum lunch intake, post-meal appetite ratings, and food reward scales. Missing data were handled via jump-to-reference multiple imputation with ANCOVAs controlling for baseline.
Study Limitations
The summary is based on the abstract only, as the full text was not available. The study was conducted at a single academic center, which may limit generalizability. Laboratory meal assessments may not accurately capture real-world free-living dietary behavior.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.